Randomized Phase II Trial of Anti-LAG-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma
- Sponsor:
- Alliance for Clinical Trials in Oncology
- Sponsor Study ID:
- A072201
- CTO #:
- 104132
- NCT Number:
- NCT06325683
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Brain and Nervous System
- Study Objectives:
- To compare the restricted mean survival time (RMST) for overall survival (OS) between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine).
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Lindhorst, Scott, at lindhors@musc.edu .
- Study Coordinator, Newman, Eva, at newmanev@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina